The enclosed application describes a series of studies to investigate the potential mechanisms of action of the recombinant human interleukin-4 receptor (rhuIL-4R) in asthma. These studies will be performed in association with a clinical trial of rhu-IL-4R in asthma sponsored by Immunex Corp. The applicants hypothesize that the administration of rhuIL-4R by nebulization produces clinical improvement in asthma, which is mediated through inhibition of Th2 lymphocytes in the lung. The clinical trail (Immunex protocol 13.0011) will evaluate the clinical efficacy of rhuIL-4R in a randomized, double blind, placebo-controlled phase II trial of 12 weekly nebulized doses of rhuIL-4R, 500 or 1500 micograms, in patients with mild and moderate allergic asthma. Evaluations will include the effects of IL-4R on spirometric measures, asthma symptoms, quality of life, and serum inflammation parameters in bronchoscopically obtained specimens taken before and after the clinical trial. The data from these subjects will be supplemented with data obtained from other patients subjected to segmental allergen challenge with or without treatment with rhuIL-4R. Interleukin (IL)-4 is essential both for the differentiation of Th2-like lymphocytes and for the inhibition of apoptosis of established Th2 cells. Neutralization of IL-4 within the asthmatic airway should therefore lead to rapid disappearance of identifiable Th2-like cells and their associated cytokines. The applicant will attempt to confirm the hypothesis that rhuIL-4R inhibits Th2-like cellular differentiation and function by assessing whether such treatment inhibits production of the Th2-associated cytokines IL-3, IL-4, IL-5, IL-9, and GM-CSF. These studies will also assess whether rhuIL-4R will induce apoptosis, as demonstrated as fragmentation of DNA, enhanced production of IL-10, up-regulated expression of CTLA4 and Fas (CD95), and down-regulation of Bcl-2. Decreased biological activity of IL-4 may also be manifested as reduced expression of VCAM-1 on bronchial epithelial tissue and decreased release of CD23 from B lymphocytes and monocytes into BAL fluid. If the treatment results in decreased production of IL-5 and other eosinophil-activating cytokines, this in turn should result in diminished expression of VCAM-1 and reduced eosinophil recruitment into the airway. Finally, we propose to correlate clinical responsiveness to rhuIL-4R with specific polymorphisms involved in interleukin-4 signaling, including IL-4, IL-4 receptor, stat-6, and bcl-6 genes. We hypothesize that individuals who are genetically predisposed to either increased IL-4 production or IL-4 responsiveness will represent a cohort more likely to benefit from the IL-4 antagonists.
| Steinke, John W; Borish, Larry (2015) Factors driving the aspirin exacerbated respiratory disease phenotype. Am J Rhinol Allergy 29:35-40 |
| Steinke, John W; Negri, Julie; Liu, Lixia et al. (2014) Aspirin activation of eosinophils and mast cells: implications in the pathogenesis of aspirin-exacerbated respiratory disease. J Immunol 193:41-7 |
| Steinke, John W; Liu, Lixia; Huyett, Phillip et al. (2013) Prominent role of IFN-? in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 132:856-65.e1-3 |
| Borish, Larry; Ayars, Andrew G; Kirkpatrick, Charles H (2011) Common variable immunodeficiency presenting as herpes simplex virus encephalitis. J Allergy Clin Immunol 127:541-3 |
| Payne, Spencer C; Han, Joseph K; Huyett, Phillip et al. (2008) Microarray analysis of distinct gene transcription profiles in non-eosinophilic chronic sinusitis with nasal polyps. Am J Rhinol 22:568-81 |
| Little, Stewart C; Early, S Brandon; Woodard, Charles R et al. (2008) Dual action of TGF-beta1 on nasal-polyp derived fibroblasts. Laryngoscope 118:320-4 |
| Early, S Brandon; Hise, Kathleen; Han, Joseph K et al. (2007) Hypoxia stimulates inflammatory and fibrotic responses from nasal-polyp derived fibroblasts. Laryngoscope 117:511-5 |
| Early, S Brandon; Barekzi, Elizabeth; Negri, Julie et al. (2007) Concordant modulation of cysteinyl leukotriene receptor expression by IL-4 and IFN-gamma on peripheral immune cells. Am J Respir Cell Mol Biol 36:715-20 |
| Barekzi, Elizabeth; Roman, Jessica; Hise, Kathleen et al. (2006) Lysophosphatidic acid stimulates inflammatory cascade in airway epithelial cells. Prostaglandins Leukot Essent Fatty Acids 74:357-63 |
| Steinke, John W; Negri, Julie; Enelow, Richard et al. (2006) Proinflammatory effects of IL-4 antagonism. J Allergy Clin Immunol 118:756-8 |
Showing the most recent 10 out of 19 publications
